Compare Heron Therapeutics Inc (HRTX) vs MasTec Inc (MTZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs MasTec Inc — how do they compare? Heron Therapeutics Inc trades at $0.37 (market cap $74.04M), while MasTec Inc trades at $218.15 (market cap $17.94B). The key difference: MasTec Inc is far larger — about 242.3× Heron Therapeutics Inc's market cap, and Heron Therapeutics Inc is more actively traded (3,668,095 versus 1,292,386). Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and MasTec Inc for 23 Days on average.
| HRTX | MTZ | |
|---|---|---|
Market Cap | $74.04M | $17.94B |
Volume | 3,668,095 | 1,292,386 |
Sector | Health | Industrials |
52-Week High | $1.49 | $437.51 |
52-Week Low | $0.27 | $190.08 |
Typical Hold Time | 35 Days | 23 Days |
Enterprise Value | $180.78M | $20.86B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.39, up 17.58% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings performance discussions.
The outlook is mixed: strong analyst support and technical momentum suggest potential upside, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on revenue growth translating to profitability, while key risks include execution challenges and competitive pressures in the biotechnology sector.
MasTec (MTZ) trades at $223.37, down 2.16% today, with technical indicators showing a neutral bias amid mixed moving average signals. The company reported strong Q1 2026 earnings beat but missed Q2 expectations, while maintaining robust revenue growth projections for 2026. Analyst sentiment remains overwhelmingly positive with 88.9% buy ratings and a $408.58 consensus price target representing significant upside potential from current levels.
MTZ's infrastructure expertise positions it well for AI-driven data center and utility investment cycles, though premium valuation metrics and recent cash flow volatility present near-term risks. The stock's investment case hinges on execution of record backlog and margin expansion amid competitive infrastructure markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About MasTec Inc
MasTec, Inc. is a leading infrastructure construction company operating mainly in North America. The company's services cover a diverse range of end-markets, including communications (building fiber and wireless infrastructure), oil & gas, electric power (transmission, distribution, and clean energy), and industrial projects. MTZ provides critical engineering, procurement, and construction (EPC) services that support the expansion and maintenance of essential infrastructure across the continent.
Read more on MTZ →
